A leading inhalation expert

Iconovo develops inhalation medicines in strategic partnership with other pharmaceutical companies. Combining our diverse portfolio of patented dry powder inhalers with considerable drug formulation expertise, we have the capacity for end-to-end product development[AM1.1] in this area. While our roots are in respiratory care, we also increasingly aim to unlock value in other therapeutic areas where inhalation offers a superior method of administration.

The advantages of using inhalation for systemic delivery include:
● More patient-friendly than injections
● More Precise dosing and faster uptake and more rapid effect than oral formulations

In the coming decade, a formidable patent cliff awaits Big Pharma with many high selling biologics losing exclusivity. These large molecules are often not possible to administer in oral format as they are quickly metabolized in the gut. Inhaled versions, however, provide possibilities and clear advantages over injections. One such project in our pipeline is inhaled semaglutide, the active substance in Ozempic®.